The Strategic Value of ADAP-Funded Insurance: Clinical Excellence & Fiscal Sustainability

Developed by NASTAD in collaboration with The AIDS Institute, this fact sheet makes the evidence-based case for why AIDS Drug Assistance Programs (ADAPs) should function as strategic insurance purchasers — not just medication providers.

Drawing on CY2024 national data, the resource demonstrates that ADAP clients supported through health care coverage achieve a 91% viral suppression rate, far outpacing both the full-pay medication-only model (86%) and the national average for all people living with HIV/AIDS (67%). The fact sheet also documents the fiscal logic behind insurance purchasing: by leveraging ACA Premium Tax Credits and 340B manufacturer rebates, ADAPs have transformed insurance premiums into a flexible revenue engine that now accounts for more than 50% of total ADAP budgets nationally.

The resource is a practical tool for ADAP administrators, Ryan White HIV/AIDS Program (RWHAP) Part B grantees, and advocates making the case to preserve and expand ADAP insurance purchasing programs. It outlines how 340B rebate revenues are reinvested across the HIV care continuum — strengthening the safety net, expanding community partnerships, and driving clinical quality improvements aligned with Ending the HIV Epidemic goals.